MG132 is a potent, reversible, cell-permeable proteasome inhibitor (IC50=100 nM), more than 1000-fold more potent than ZLLal in inhibiting the ZLLL-MCA degradation activity of the 20S proteasome. MG132 also inhibits the cell cycle and calpain required for cyclin degradation (IC50=1.2 μM), and induces neurite outgrowth in PC12 cells. In addition, MG132 inhibited IκBα degradation, thereby inhibiting NF-κB pathway activation. MG132 induces apoptosis of MPM cells with the activation of caspase 3/7/8/9 proteins. In addition to inducing apoptosis, MG132 also induced changes in mitochondrial membrane potential and increased intracellular ROS levels. Features Purity≥96% Standardized production, using factory mass production mode Specifications Cat.No. 52801ES08/52801ES10/52801ES25/52801ES50/52801ES60 Size 5 mg/10 mg/25 mg/50 mg/100 mg Synonym N-[(Phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-L-leucinamide; Z-Leu-Leu-Leu-al; Z-Leu-Leu-Leu-CHO Target Proteasome CAS No. 133407-82-6 Molecular formula C26H41N3O5 Molecular weight 475.6 Appearance solid powder Purity ≥96% Solubility Soluble in DMSO Structure Components Components No. Name 52801ES08 52801ES10 52801ES25 52801ES50 52801ES60 52801 MG132 (MG-132) 5 mg 10 mg 25 mg 50 mg 100 mg Shipping and Storage The MG132 (MG-132) products should be stored at -15～-25℃ for 2 years. Avoid repeated freeze-thaw cycles. Documents: Safety Data Sheet 52801_MSDS_HB20250210 _EN.pdf Manuals 52801_Manual_HB20250210 _EN.pdf
